{"entity":{"id":"pou2af1","kind":"target","name":"POU2AF1","aka":["POU class 2 homeobox associating factor 1","POU domain class 2-associating factor 1","OBF1","BOB1","OCA-B"],"tldr":"POU2AF1 (POU domain class 2-associating factor 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Skin cancer and 1 more.","summary":"Transcriptional coactivator that specifically associates with either POU2F1/OCT1 or POU2F2/OCT2. It boosts the POU2F1/OCT1 mediated promoter activity and to a lesser extent, that of POU2F2/OCT2. It recognises the POU domains of POU2F1/OCT1 and POU2F2/OCT2.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.59 (direct and indirect evidence; datatypes literature 0.46, genetic association 0.00, somatic mutation 0.95).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:9211","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9211"},{"label":"UniProt Q16633","url":"https://www.uniprot.org/uniprotkb/Q16633/entry"},{"label":"NCBI Gene 5450","url":"https://www.ncbi.nlm.nih.gov/gene/5450"},{"label":"Ensembl ENSG00000110777","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110777"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets"],"cancers":["non-hodgkin-lymphoma","lung-cancer","skin-cancer","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"POU2AF1","role":["biomarker","fusion-partner"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:9211","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9211","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q16633","url":"https://www.uniprot.org/uniprotkb/Q16633/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene POU2AF1","url":"https://civicdb.org/features/4409","note":"1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000110777","url":"https://platform.opentargets.org/target/ENSG00000110777/associations","note":"association with cancer (MONDO_0004992) 0.59; per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.54, skin cancer 0.50, lung cancer 0.51 (GraphQL API, CC0)"}],"specificity":"tumour-specific","distribution":"few-types","specificityNote":"Tumour-specific alteration: the catalogues call it a fusion partner (UniProt records a translocation); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA POU2AF1: RNA group enriched (intestine 41 nTPM, lymphoid tissue 112 nTPM, stomach 1 38 nTPM); blood lineage lineage enriched (B-cells 34 nTPM); high antibody staining in 3 normal tissues; highest cancer staining melanoma (4 of 11 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Lung cancer (all types), Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"UniProt Q16633","url":"https://www.uniprot.org/uniprotkb/Q16633/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene POU2AF1","url":"https://civicdb.org/features/4409","note":"1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)"},{"label":"Human Protein Atlas POU2AF1 tissue","url":"https://www.proteinatlas.org/ENSG00000110777-POU2AF1/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000110777 associations","url":"https://platform.opentargets.org/target/ENSG00000110777/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:9211","ensembl":"ENSG00000110777","uniprot":"Q16633","entrez":"5450","firstDescribed":1995,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Strubin et al, Cell, 1995, \"OBF-1, a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/7859290/","biology":"Transcriptional coactivator that specifically associates with either POU2F1/OCT1 or POU2F2/OCT2. It boosts the POU2F1/OCT1 mediated promoter activity and to a lesser extent, that of POU2F2/OCT2. It recognises the POU domains of POU2F1/OCT1 and POU2F2/OCT2. It is essential for the response of B-cells to antigens and required for the formation of germinal centres. Regulates IL6 expression in B cells as POU2F2/OCT2 coactivator. Location: Nucleus (UniProt). Locus 11q23.1 (HGNC).","whereFound":["Non-Hodgkin lymphoma: Open Targets association 0.54 with non-Hodgkin lymphoma (MONDO_0018908)","Lung cancer: Open Targets association 0.51 with lung cancer (MONDO_0008903)","Skin cancer: Open Targets association 0.50 with skin cancer (MONDO_0002898)","Diffuse large B-cell lymphoma: CIViC evidence names this disease"],"targetClass":"transcription","prevalence":[]},"route":"/targets/pou2af1/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}]}}